SemBioSys announces senior management change

18-Jan-2010 - SemBioSys Genetics Inc. announced that effective March 25, 2010, Professor Maurice Moloney, Ph.D., the Company's Founder and Chief Scientific Officer has accepted a full-time position with the Biotechnology and Biological Sciences Research Council (BBSRC) and the Lawes Trust in the United Kingdom ...

SemBioSys begins phase I/II trial of insulin produced in plant seeds

05-Dec-2008 - SemBioSys Genetics Inc. announced that it has initiated a phase I/II clinical trial of its plant-produced insulin with the first injection of its drug in humans. The trial, taking place in the United Kingdom (UK), will include up to 30 healthy volunteers in a three-arm study (SBS-1000 insulin and ...

SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office

18-Mar-2008 - SemBioSys Genetics Inc. announced that it has been granted European patent EP0986309(B1) entitled "Uses of Oil Bodies". The patent has been issued to SemBioSys, which has exclusively licensed commercial rights associated with the patent to Botaneco Specialty Ingredients Inc., its wholly owned ...

Plants produce recombinant apolipoprotein AI on a commercial level

Canadian SemBioSys achieves critical milestone

16-Jul-2007 - SemBioSys Genetics Inc. has successfully developed commercial levels of apolipoprotein AI and its variant apolipoprotein AI (Milano) (collectively referred to as Apo AI) in safflower seed lines. Apo AI is believed by many clinicians to be the basis for the next generation of cardiovascular drugs, ...

SemBioSys signs contract manufacturing agreement for plant-produced insulin with Cangene

27-Nov-2006 - SemBioSys Genetics Inc. announced the completion of a Technology Transfer and Manufacturing Agreement with Cangene Corporation for the processing and purification of SemBioSys' plant-produced insulin. The contract is part of the Company's preparations for its Investigational New Drug Application ...

SemBioSys achieves major insulin milestone

Canadian Biotechnology Company achieves commercially viable level of insulin in safflower

20-Jul-2006 - SemBioSys Genetics Inc. has achieved its commercial target levels of human insulin (insulin) accumulation in safflower with 1.2 percent of total seed protein. The results from the Company's commercial plant system exceeded its target of one percent accumulation and confirm the potential of ...

SemBioSys obtains rights to platform-enhancing technologies from Syngenta

Canadian Biotechnology Company to expedite development process for biopharmaceuticals

19-Jun-2006 - SemBioSys Genetics Inc., a biotechnology company developing a pipeline of protein-based pharmaceuticals and non-pharmaceutical products, announced an agreement to acquire technology assets and in-license intellectual property related to the manufacture of biopharmaceuticals in safflower from ...